1. National Center for Health Statistics. Health, United States 2015 With Special Feature on Racial and Ethnic Health Disparities. Hyattsville, MD: US Dept. Health and Human Services; 2016. http://www.cdc.gov/nchs/hus/ . Accessed October 17, 2016.
2. Khialani B, Sivakumaran P, Keijzers G, Sriram KB. Emergency department management of acute exacerbations of chronic obstructive pulmonary disease and factors associated with hospitalization. J Res Med Sci . 2014;19(4):297-303.
3. World Health Organization Web site. Chronic respiratory diseases. COPD: Definition. http://www.who.int/respiratory/copd/definition/en/ . Accessed October 17, 2016.
4. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med . 2007;176(6):532-555.
5. Fan VS, Ramsey SD, Make BJ, Martinez FJ. Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD . 2007;4(1):29-39.
6. Cydulka RK, Rowe BH, Clark S, Emerman CL, Camargo CA Jr; MARC Investigators. Emergency department management of acute exacerbations of chronic obstructive pulmonary disease in the elderly: the Multicenter Airway Research Collaboration. J Am Geriatr Soc . 2003;51(7):908-916.
7. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest . 2001;119:3.
8. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med . 2009;360(14):1418-1428. doi:10.1056/NEJMsa0803563.
9. Rowe BH, Bhutani M, Stickland MK, Cydulka R. Assessment and management of chronic obstructive pulmonary disease in the emergency department and beyond. Expert Rev Respir Med . 2011;5(4):549-559. doi:10.1586/ers.11.43.
10. National Institute for Clinical Excellence Web site. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Clinical Guideline CG101. https://www.nice.org.uk/Guidance/cg101 . Published June 2010. Accessed October 17, 2016.
11. Christensen VL, Holm AM, Cooper B, Paul SM, Miaskowski C, Rustøen T. Differences in symptom burden among patients with moderate, severe, or very severe chronic obstructive pulmonary disease. J Pain Symptom Manage . 2016;51(5):849-859. doi:10.1016/j.jpainsymman.2015.12.324.
12. GOLD Reports. Global Initiative for Chronic Obstructive Lung Disease Web site. http://goldcopd.org/gold-reports /. Accessed October 17, 2016.
13. Funk GC, Kirchheiner K, Burghuber OC, Hartl S. BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD—a cross-sectional study. Respir Res . 2009;10:1. doi:10.1186/1465-9921-10-1.
14. Bach PB, Brown C, Gelfand SE, McCrory DC; American College of Physicians-American Society of Internal Medicine; American College of Chest Physicians. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med . 2001;134(7):600-620.
15. McCrory DC, Brown CD. Inhaled short-acting beta 2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2001;(2):CD002984.
16. Shivanthan MC, Rajapakse S. Magnesium for acute exacerbation of chronic obstructive pulmonary disease: A systematic review of randomised trials. Ann Thorac Med . 2014;9(2):77-80. doi:10.4103/1817-1737.128844.
17. Curtis JR. Palliative and end of life care for patients with severe COPD. Eur Respir J . 2008;32(3):796-803.
18. Rocker GM, Simpson AC, Young J, et al. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ Open . 2013;1(1):E27-E36.
19. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnea. Thorax . 2002;57(11):939-944.
20. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ . 2003;327(7414):523-528.
21. Qaseem A, Wilt TJ, Weinberger SE, et al; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med . 2011;155(3):179-191. doi:10.7326/0003-4819-155-3-201108020-00008.
22. National POLST Paradigm. http://polst.org/professionals-page/?pro=1 . Accessed October 17, 2016.
23. Hansen-Flaschen J. Chronic obstructive pulmonary disease: the last year of life. Respir Care . 2004;49(1):90-97; discussion 97-98.
24. Spathis A, Booth S. End of life care in chronic obstructive pulmonary disease: in search of a good death. Int J Chron Obstruct Pulmon Dis . 2008;3(1):11-29.
25. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care . 1996;12(1):5-11.
